ArticleCommunications medicine2025
Association between mental health and MASLD molecular insights through metabolomics.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- A cardiometabolic risk phenotype index integrating insulin resistance, systemic inflammation, and psychological burden for mortality risk stratification in metabolic dysfunction-associated steatotic liver disease: an exploratory longitudinal analysis of a nationally representative cohort.Lipids in health and disease · 2026Article
- Is MASLD Not Just a Liver Disease? Bidirectional Gut-Liver Crosstalk as a Driver of Chronic Liver Disease.Life (Basel, Switzerland) · 2026Review
- Cardiac substructure dosimetry in thoracic radiotherapy: moving beyond mean heart dose and toward precision cardiac risk mitigation.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Review
- The liver-gut-brain axis in metabolic dysfunction-associated steatotic liver disease: bidirectional communication, clinical implications, and future perspectives.Frontiers in endocrinology · 2026Review
- Associations of cardiometabolic burden with cardiovascular disease-death transitions in metabolic dysfunction-associated steatotic liver disease: a prospective cohort study using multistate analysis.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMental health disorders and metabolic dysfunction-associated steatotic liver disease (MASLD) represent substantial global public health challenges. The precise relationship between mental health parameters and MASLD development remains poorly characterized.
methodsUsing data from the UK Biobank cohort, we conducted a prospective cohort study to evaluate participants' anxiety, depression, mania, and trauma exposure scores using standardized psychometric instruments. Metabolic signatures were derived through elastic net regularization coupled with Cox proportional hazards modeling. Mediation analyses quantified the proportion of mental health-MASLD associations attributable to metabolic pathway alterations.
resultsThe analytical cohort comprises 55,012 participants with trauma assessments, 15,318 with mania evaluations, 30,798 with depression metrics, and 17,596 with anxiety profiles. Multivariable-adjusted analyses reveal significant dose-response relationships between mental health burden and MASLD incidence: anxiety (HR = 1.13, 95%CI 1.08-1.18, P < 0.05), depression (HR = 1.06, 95%CI 1.03-1.10, P < 0.05), mania (HR = 1.15, 95%CI 1.06-1.24, P < 0.05), and trauma (HR = 1.22, 95%CI 1.11-1.34, P < 0.05). Metabolic analyses indicate that creatinine, glutamine, and the triglyceride fraction of very low-density lipoprotein (VLDL-triglyceride%) serve as key mediators in the pathway through which mental health influences MASLD incidence. The derived metabolic signature demonstrates significant mediation effects across all psychological domains (anxiety: 12.7%, depression: 15.7%, mania: 11.5%, trauma: 11.2%).
conclusionsThis large-scale cohort study establishes clinically significant mental health conditions as risk factors for MASLD development, with metabolic dysregulation serving as a partial mediator of this association. The identified metabolite panel, particularly perturbations in nitrogen metabolism and lipid partitioning, provides mechanistic insights into psychosomatic pathways influencing hepatic steatosis, suggesting potential targets for interdisciplinary intervention strategies.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.